pashtun

VSAR - Long Opportunity

NASDAQ:VSAR   None
Versartis Inc, had a clinical trial that failed, same deal with AXON and few others, but they still have 3 or 4 trials pending. Dont think it would fall lower. If they have trials left but not that good at these kind of plays. Keep an eye on this one forsure. Might just hold a small lot, 52 week high was 24 $.
면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.